Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Terpos · SciRah

Researcher profile · Semantic Scholar

E. Terpos

Share profile

E. Terpos — researcher profile on SciRah

h-index: 104
Works: 1,365
Citations: 50K

Most-cited papers

Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
M. Dimopoulos, G. Merlini, F. Bridoux, N. Leung +23 more
2023The Lancet Oncology140 citations Open access
Semantic Scholar
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial
E. Zamagni, T. Silzle, I. Špička, S. Tahri +47 more
2024Blood34 citations
Semantic Scholar
Prognosis of COVID-19 severity using DERGA, a novel machine learning algorithm.
P. Asteris, Amir H. Gandomi, D. J. Armaghani, Styliani Kokoris +14 more
2024European journal of internal medicine33 citations
Semantic Scholar
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled Trials
I. Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, P. Malandrakis +5 more
2025American journal of hematology/oncology30 citations Open access
Semantic Scholar
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin
P. Efentakis, A. Choustoulaki, Grzegorz Kwiatkowski, A. Varela +15 more
2024Basic Research in Cardiology29 citations Open access
Semantic Scholar
Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma.
E. Terpos, P. Malandrakis, I. Ntanasis-Stathopoulos, Ioannis V. Kostopoulos +10 more
2025Blood27 citations
Semantic Scholar
Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network.
N. V. van de Donk, P. Moreau, J. San-Miguel, María-Victoria Mateos +31 more
2025The Lancet Haematology24 citations Open access
Semantic Scholar
Genetic justification of COVID‐19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm
P. Asteris, Amir H. Gandomi, D. J. Armaghani, M. Tsoukalas +24 more
2024Journal of Cellular and Molecular Medicine23 citations Open access
Semantic Scholar
Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group
E. Katodritou, D. Dalampira, S. Delimpasi, I. Ntanasis-Stathopoulos +21 more
2024American journal of hematology/oncology21 citations
Semantic Scholar
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
N. V. van de Donk, P. Moreau, J. San-Miguel, M. Mateos +35 more
2025HemaSphere20 citations Open access
Semantic Scholar
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
Heinz Ludwig, Nikhil C. Munshi, E. Terpos, Ilvy Schweitzer +3 more
2024Blood Advances20 citations Open access
Semantic Scholar
The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma
Panagiotis Malamos, C. Papanikolaou, M. Gavriatopoulou, M. Dimopoulos +2 more
2024International Journal of Molecular Sciences19 citations Open access
Semantic Scholar
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma.
D. Kegyes, D. Gulei, Rareș Drula, D. Cenariu +11 more
2023Blood reviews18 citations
Semantic Scholar
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
E. Terpos, I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Katodritou +10 more
2024American journal of hematology/oncology17 citations Open access
Semantic Scholar
Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).
C. Touzeau, M. Beksaç, E. Terpos, S. Usmani +15 more
2024Journal of Clinical Oncology17 citations Open access
Semantic Scholar
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis +11 more
2024Haematologica16 citations Open access
Semantic Scholar
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches
Sareh Kakavandi, Bahareh Hajikhani, Paniz Azizi, F. Aziziyan +9 more
2024Cell Communication and Signaling14 citations Open access
Semantic Scholar
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
J. Kiladjian, F. Marín, H. Al-Ali, A. Álvarez-Larrán +37 more
2024Annals of Hematology14 citations Open access
Semantic Scholar
Patterns of progression among 427 patients with smoldering myeloma diagnosed after 2014: importance of monitoring
E. Kastritis, I. Solia, P. Malandrakis, F. Theodorakakou +12 more
2025Blood Advances13 citations Open access
Semantic Scholar
Evaluating Minimal Residual Disease Negativity As a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
I. Ntanasis-Stathopoulos, Charalampos Filippatos, Anastasios Ntanasis-Stathopoulos, P. Malandrakis +4 more
2024Blood13 citations
Semantic Scholar
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma
Ioannis V. Kostopoulos, I. Ntanasis-Stathopoulos, P. Rousakis, P. Malandrakis +16 more
2024American journal of hematology/oncology13 citations Open access
Semantic Scholar
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
L. Bertamini, C. Fokkema, P. Rodríguez-Otero, M. van Duin +22 more
2025Blood11 citations Open access
Semantic Scholar
Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity
P. Efentakis, A. Varela, S. Lamprou, Eleni-Dimitra Papanagnou +8 more
2024British Journal of Pharmacology11 citations Open access
Semantic Scholar
Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network
G. Gerotziafas, D. Fotiou, I. Nijhof, C. Ay +19 more
2025HemaSphere9 citations Open access
Semantic Scholar
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis, D. Fotiou +10 more
2024American journal of hematology/oncology9 citations
Semantic Scholar
Thrombotic and bleeding complications in patients with AL amyloidosis
D. Fotiou, F. Theodorakakou, S. Spiliopoulou, M. Gavriatopoulou +10 more
2024British Journal of Haematology8 citations Open access
Semantic Scholar
Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review.
M. Mainou, Kalliopi Tsapa, T. Michailidis, K. Malandris +7 more
2024Critical reviews in oncology/hematology8 citations Open access
Semantic Scholar
Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study
P. Malandrakis, I. Ntanasis-Stathopoulos, Ioannis V. Kostopoulos, Vasiliki Spiliopoulou +10 more
2024Blood7 citations
Semantic Scholar
Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment outcome
Konstantinos Soureas, M. Papadimitriou, P. Malandrakis, A. Papanota +10 more
2024British Journal of Haematology7 citations Open access
Semantic Scholar
Single‐cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients
T. Bagratuni, Foteini Aktypi, Ourania Theologi, Maria Sakkou +13 more
2024HemaSphere7 citations Open access
Semantic Scholar
High-Oxygen-Affinity Hemoglobins—Case Series and Review of the Literature
V. Komninaka, P. Flevari, Evangelia‐Eleni Ntelaki, Eleni Yfanti +3 more
2024Journal of Clinical Medicine7 citations Open access
Semantic Scholar
Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line Treatment
Polyxeni Spiliopoulou, P. Rousakis, C. Panteli, E. Eleutherakis-Papaiakovou +12 more
2025Scandinavian Journal of Medicine & Science in Sports6 citations Open access
Semantic Scholar
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
X. Leleu, Hans C. Lee, J. Zonder, M. Macro +9 more
2024Future Oncology6 citations Open access
Semantic Scholar
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
Maria Papatsirou, C. Kontos, I. Ntanasis-Stathopoulos, P. Malandrakis +8 more
2024HemaSphere6 citations Open access
Semantic Scholar
ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma
Maria Papatsirou, C. Kontos, I. Ntanasis-Stathopoulos, P. Malandrakis +10 more
2024eJHaem6 citations Open access
Semantic Scholar
Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
Konstantinos Soureas, P. Malandrakis, M. Papadimitriou, Christos Minopoulos +8 more
2025Blood Cancer Journal5 citations Open access
Semantic Scholar
ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options
J. Kiladjian, F. Ferrer-Marín, H. Al-Ali, A. Álvarez-Larrán +37 more
2024Blood5 citations
Semantic Scholar
Circulating Ferritin in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Eleftheria Makri, Myrsini Orfanidou, Evangelia S. Makri, A. Goulas +2 more
2024Journal of Clinical and Experimental Hepatology5 citations
Semantic Scholar
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies
F. Theodorakakou, D. Fotiou, Vasiliki Spiliopoulou, M. Migkou +15 more
2025Amyloid: Journal of Protein Folding Disorders4 citations
Semantic Scholar
Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire.
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, P. Malandrakis +10 more
2024Journal of Clinical Oncology4 citations
Semantic Scholar
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG).
E. Kastritis, M. Beksaç, S. Bădeliţă, E. Katodritou +20 more
2024Clinical Lymphoma, Myeloma & Leukemia4 citations
Semantic Scholar
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
María-Victoria Mateos, K. Weisel, E. Terpos, S. Delimpasi +12 more
2024Haematologica4 citations Open access
Semantic Scholar
Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Pers
L. Bertamini, C. Fokkema, P. Rodríguez-Otero, M. van Duin +22 more
2024Blood4 citations
Semantic Scholar
Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring Dialysis.
D. Fotiou, F. Theodorakakou, E. Solia, Vasiliki Spiliopoulou +13 more
2025Clinical Lymphoma, Myeloma & Leukemia3 citations Open access
Semantic Scholar
Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice
I. Ntanasis-Stathopoulos, V. Koutoulidis, P. Malandrakis, D. Fotiou +11 more
2025Journal of Clinical Medicine3 citations Open access
Semantic Scholar
A prospective study of small fiber neuropathy in AL amyloidosis
C. Bountziouka, D. Fotiou, F. Theodorakakou, A. Papanikolaou +5 more
2025Amyloid: Journal of Protein Folding Disorders3 citations
Semantic Scholar
Long-term Survival in a Patient With Transformation of Waldenström's Macroglobulinemia into DLBCL.
E. Solia, I. Ntanasis-Stathopoulos, E. Kastritis, E. Terpos +2 more
2024Cancer Diagnosis & Prognosis3 citations Open access
Semantic Scholar
A hypothesis on treatment strategy of severe multicentric Castleman disease with continuous renal replacement therapy
C. Constantinescu, D. Kegyes, B. Tigu, Vlad Moisoiu +4 more
2024Journal of Cellular and Molecular Medicine3 citations Open access
Semantic Scholar
Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)
E. Kastritis, E. Katodritou, S. Bădeliţă, Jelena Bila +16 more
2024Leukemia and Lymphoma2 citations
Semantic Scholar
Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
E. Terpos, I. Ntanasis-Stathopoulos, C. Kyriakou, C. Tan +7 more
2024Blood2 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Kastritis×27
Invite
E. Kastritis — researcher profile on SciRah
M. Gavriatopoulou×27
Invite
M. Gavriatopoulou — researcher profile on SciRah
M. Dimopoulos×26
Invite
M. Dimopoulos — researcher profile on SciRah
I. Ntanasis-Stathopoulos×26
Invite
I. Ntanasis-Stathopoulos — researcher profile on SciRah

×19

Invite

P. Malandrakis — researcher profile on SciRah

Invite

M. Migkou — researcher profile on SciRah

F. Theodorakakou×14

Invite

F. Theodorakakou — researcher profile on SciRah

Invite

D. Fotiou — researcher profile on SciRah

E. Eleutherakis-Papaiakovou×12

Invite

E. Eleutherakis-Papaiakovou — researcher profile on SciRah

N. Kanellias×10

Invite

N. Kanellias — researcher profile on SciRah

Invite

M. Beksaç — researcher profile on SciRah

N. V. van de Donk×8

Invite

N. V. van de Donk — researcher profile on SciRah